BBIO Stock Analysis: BridgeBio Pharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 15.253m USD | 12M Return: 18.9% | US10806X1028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 203M
Qual. Beats: 1
Rev. Trend: 79.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 7.4 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a U.S.-based biopharmaceutical company headquartered in Palo Alto, California, founded in 2015. The company focuses on discovering, developing, and commercializing medicines for patients with genetic diseases, with a pipeline spanning multiple therapeutic modalities including small molecules, gene therapy, and biologics.
BridgeBio markets Attruby, an oral TTR stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), and NULIBRY (Fosdenopterin) for molybdenum cofactor deficiency, a rare metabolic disorder. The companys late-stage pipeline includes low-dose infigratinib (Phase 3) for achondroplasia, Encaleret (Phase 3) for hypocalcemia disorders, BBP-418 (Phase 3) for limb-girdle muscular dystrophy type 2I (LGMD2I), and BBP-812, an AAV-based gene therapy for Canavan disease.
BridgeBio pursues licensing and collaboration agreements with major pharmaceutical partners including Bayer, Alexion, Stanford University, and Novartis, a common strategy among biotechnology companies to share development risk and accelerate commercialization. The company operates within the GICS Biotechnology sub-industry and completed its IPO in June 2019, reflecting the capital-intensive nature of genetic disease drug development, which often requires extended R&D timelines before products reach market.
- Attruby launch drives early commercial revenue growth
- Phase 3 readouts for infigratinib and encaleret near
- High cash burn requires continued capital raises
- Competition in ATTR-CM market from Pfizers tafamidis
- Pipeline expansion through licensing deals with Bayer and Novartis
- Regulatory approvals and label expansions for NULIBRY and Attruby
| Net Income: -570.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA 42.31 > 1.0 |
| NWC/Revenue: 112.9% < 20% (prev 176.0%; Δ -63.15% < -1%) |
| CFO/TA -0.17 > 3% & CFO -369.0m > Net Income -570.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (196.0m) vs 12m ago 2.89% < -2% |
| Gross Margin: 93.51% > 18% (prev 95.78%; Δ -2.26% > 0.5%) |
| Asset Turnover: 59.84% > 50% (prev 35.44%; Δ 24.40% > 0%) |
| Interest Coverage Ratio: -3.33 > 6 (EBIT TTM -445.3m / Interest Expense TTM 133.6m) |
| A: 0.49 (Total Current Assets 2.04b - Total Current Liabilities 977.2m) / Total Assets 2.16b |
| B: -1.94 (Retained Earnings -4.19b / Total Assets 2.16b) |
| C: -0.28 (EBIT TTM -445.3m / Avg Total Assets 1.58b) |
| D: -0.44 (Book Value of Equity -1.66b / Total Liabilities 3.82b) |
| Altman-Z'' = -5.44 = D |
| DSRI: 1.20 (Receivables 375.1m/116.5m, Revenue 945.5m/353.8m) |
| GMI: 1.02 (GM 95.78% / 93.51%) |
| AQI: 0.30 (AQ_t 0.04 / AQ_t-1 0.15) |
| SGI: 2.67 (Revenue 945.5m / 353.8m) |
| TATA: -0.09 (NI -570.2m - CFO -369.0m) / TA 2.16b) |
| Beneish M = -2.06 (Cap -4..+1) = BB |
As of November 19, 2026, the stock is trading at USD 78.01 with a total of 3,547,072 shares traded. Over the past week, the price has changed by -1.92%, over one month by +14.82%, over three months by -5.99% and over the past year by +18.94%.
Current recommended Stop Loss: 74.70 (which is 4.2% or 1.2 ATR below the current price).
BridgeBio Pharma has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy BBIO.
- StrongBuy: 14
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 106.9 | 37% |
P/S = 16.1314
P/B = 123.6828
Revenue TTM = 945.5m USD
EBIT TTM = -445.3m USD
EBITDA TTM = -440.6m USD
Long Term Debt = 1.93b USD (from longTermDebt, last quarter)
Short Term Debt = 550.4m USD (from shortTermDebt, last quarter)
Debt = 2.51b USD (from shortLongTermDebtTotal, last quarter) + Leases 16.6m
Net Debt = 971.8m USD (calculated: Debt 2.51b - CCE 1.54b)
Enterprise Value = 16.2b USD (15.3b + Debt 2.51b - CCE 1.54b)
Interest Coverage Ratio = -3.33 (Ebit TTM -445.3m / Interest Expense TTM 133.6m)
EV/FCF = -43.35x (Enterprise Value 16.2b / FCF TTM -374.3m)
FCF Yield = -2.31% (FCF TTM -374.3m / Enterprise Value 16.2b)
FCF Margin = -39.59% (FCF TTM -374.3m / Revenue TTM 945.5m)
Net Margin = -60.30% (Net Income TTM -570.2m / Revenue TTM 945.5m)
Gross Margin = 93.51% ((Revenue TTM 945.5m - Cost of Revenue TTM 61.3m) / Revenue TTM)
Gross Margin QoQ = 94.21% (prev 93.83%)
Tobins Q-Ratio = 7.51 (Enterprise Value 16.2b / Total Assets 2.16b)
Interest Expense / Debt = 5.32% (Interest Expense 133.6m / Debt 2.51b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -351.8m (EBIT -445.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.09 (Total Current Assets 2.04b / Total Current Liabilities 977.2m)
Debt / Equity = -1.51 (negative equity) (Debt 2.51b / totalStockholderEquity, last quarter -1.66b)
Debt / EBITDA = -2.21 (negative EBITDA) (Net Debt 971.8m / EBITDA -440.6m)
Debt / FCF = -2.60 (negative FCF - burning cash) (Net Debt 971.8m / FCF TTM -374.3m)
Total Stockholder Equity = -2.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -36.09% (Net Income -570.2m / Total Assets 2.16b)
RoE = 26.76% (negative equity) (Net Income TTM -570.2m / Total Stockholder Equity -2.13b)
RoCE = 220.7% (negative capital employed) (EBIT -445.3m / Capital Employed (Equity -2.13b + L.T.Debt 1.93b))
RoIC = -20.85% (negative operating profit) (NOPAT -351.8m / Invested Capital 1.69b)
WACC = 8.17% (E(15.3b)/V(17.8b) * Re(8.82%) + D(2.51b)/V(17.8b) * Rd(5.32%) * (1-Tc(0.21)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.08 | Cagr: 1.98%
[DCF] Fair Price = unknown (Cash Flow -374.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.10 | # QB: 1
Revenue Correlation: 79.01 | Revenue CAGR: 183.4% | SUE: 1.72 | # QB: 1
EPS current Quarter (2027-03-31): EPS=-0.37 | Chg30d=-2.08% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=-2.49 | Chg30d=+3.51% | Revisions=+62% | GrowthEPS=+34.1% | GrowthRev=+118.6%
EPS next Year (2027-12-31): EPS=-0.27 | Chg30d=N/A | Revisions=-38% | GrowthEPS=+89.0% | GrowthRev=+51.7%
[Analyst] Revisions Ratio: +21% (up=7, down=4)